期刊文献+

伊曲康唑在多器官功能障碍综合征患者侵袭性真菌感染中的应用 被引量:6

Itraconazole against invasive fungal infection in patients of multiple organ dysfunction syndrome
暂未订购
导出
摘要 目的评价伊曲康唑注射液治疗多器官功能障碍综合征(mu ltip le organ dysfunction syndrom e,MODS)患者侵袭性真菌感染的疗效及副作用。方法以伊曲康唑注射液治疗临床确诊的MODS患者侵袭性真菌感染15例,评价伊曲康唑的疗效及副作用。结果痊愈12例,显效1例,好转1例,无效(死亡)1例。在治疗过程中,未观察到不良反应。结论伊曲康唑注射液是治疗MODS患者侵袭性真菌感染安全、疗效确切的药物,值得在临床上推广使用。 Objective To evaluate the efficacy and safety of itraconazole injection in treatment of invasive fungal infection in the patients with multiple organ dysfunction syndrome. Methods Invasive fungal infection in 15 patients with multiple organ dysfunction syndrom day on the first two days, then once a day, for 8 to 14 results of chemical detection were recorded. Everyday Results The recovery rate, effective rate, and e was treated with 200 mg itraconazole injection, twice a days. During the treatment, the symptoms and signs, the fungus, sputum, stool smear or culture were performed. fungal clearance in this trial with itraconazole injection were 80% ( 12/15 ), 86.7% ( 13/15 ), and 86.7% ( 13/15 ) respectively. The side effect was not found. Conclusion Itraconazole injection is an effective and safe drug against invasive fungal infection in patients with multiple organ dysfunction syndrome.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2006年第11期1260-1261,共2页 Journal of Third Military Medical University
关键词 伊曲康唑注射液 多器官功能障碍综合征 真菌感染 itraconazole injection multiple organ dysfunction syndrome fungal infection
  • 相关文献

参考文献5

二级参考文献27

  • 1张秀珍.当代细菌检验与临床[M].北京:人民卫生出版社,1998.266-269.
  • 2Safayhi H , Mack T , Sabieraj J , et al . Boswellic acids:novel , specific , nonredox inhibitors of 52 lipoxygenase[J].J Pharmacol Exp Ther, 1992 , 261 (3) :1143.
  • 3Mattews RC, Burnie, JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy [ J ]. Vaccine,2004, 22(7): 865 - 871.
  • 4Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs [ J]. Current Opinion in Microbiology, 1998, 1(5): 547 - 557.
  • 5Ghannoum MA, Rice LB. Antifungal agents:mode of action,mechanisms of resistance, and correlation of these mechanisms with bacterial resistance [J]. Clin Microbio Rev, 1999,12(4): 501 - 517.
  • 6White TC,Marr KA,Bowden RA.Clinical,cellular,and molecular factors that contribute to antifungal drug resistance [J]. Clinical Microbiology Reviews, 1998, 11(2): 382-402.
  • 7Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanism of action [ J]. TRENDS in Microbiology, 2003, 11(6): 272 - 279
  • 8Resende JC,de Resende MA,Saliba JL. Prevalence of Candida spp in hospitalized patients and their risk factors. Mycoses, 2002,45 (8):306-312.
  • 9Seiji Kayama, Masao Mitsuyama, Nobuaki Sato, et al. Overgrowth and translocation of Escherichia coli from intestine during prolonged enteral feeding in rats. J Gastroenterol, 2000,35:15-19.
  • 10Zer Y,Balci I,Meric G. Identification and antifungal susceptibility of Candida isolated from intensive unit patients. New Microbiol, 2002,25(4) :489-494.

共引文献43

同被引文献53

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部